Orthopedics and Spine Surgery, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China.
Front Immunol. 2023 Apr 6;14:1129746. doi: 10.3389/fimmu.2023.1129746. eCollection 2023.
Severe acute respiratory syndrome-coronavirus 2 (COVID-19) vaccines may incur changes in thyroid functions followed by mood changes, and patients with Hashimoto thyroiditis (HT) were suggested to bear a higher risk.
We primarily aim to find whether COVID-19 vaccination could induce potential subsequent thyroid function and mood changes. The secondary aim was to find inflammatory biomarkers associated with risk.
The retrospective, multi-center study recruited patients with HT receiving COVID-19-inactivated vaccines. C-reactive proteins (CRPs), thyroid-stimulating hormones (TSHs), and mood changes were studied before and after vaccination during a follow-up of a 6-month period. Independent association was investigated between incidence of mood state, thyroid functions, and inflammatory markers. Propensity score-matched comparisons between the vaccine and control groups were carried out to investigate the difference.
Final analysis included 2,765 patients with HT in the vaccine group and 1,288 patients in the control group. In the matched analysis, TSH increase and mood change incidence were both significantly higher in the vaccine group (11.9% versus 6.1% for TSH increase and 12.7% versus 8.4% for mood change incidence). An increase in CRP was associated with mood change (p< 0.01 by the Kaplan-Meier method) and severity (r = 0.75) after vaccination. Baseline CRP, TSH, and antibodies of thyroid peroxidase (anti-TPO) were found to predict incidence of mood changes.
COVID-19 vaccination seemed to induce increased levels and incidence of TSH surge followed by mood changes in patients with HT. Higher levels of pre-vaccine serum TSH, CRP, and anti-TPO values were associated with higher incidence in the early post-vaccine phase.
严重急性呼吸综合征冠状病毒 2(COVID-19)疫苗接种后可能会引起甲状腺功能改变,继而引起情绪变化,桥本甲状腺炎(HT)患者被认为风险更高。
我们主要旨在确定 COVID-19 疫苗接种是否会引起潜在的后续甲状腺功能和情绪变化。次要目的是寻找与风险相关的炎症生物标志物。
这项回顾性、多中心研究招募了接受 COVID-19 灭活疫苗的 HT 患者。在 6 个月的随访期间,研究了接种前后 C 反应蛋白(CRP)、促甲状腺激素(TSH)和情绪变化。调查了情绪状态、甲状腺功能和炎症标志物之间的独立关联。对疫苗组和对照组进行了倾向评分匹配比较,以调查差异。
最终分析包括疫苗组 2765 例 HT 患者和对照组 1288 例 HT 患者。在匹配分析中,疫苗组 TSH 升高和情绪变化发生率均明显高于对照组(TSH 升高发生率分别为 11.9%和 6.1%,情绪变化发生率分别为 12.7%和 8.4%)。CRP 增加与接种后的情绪变化(Kaplan-Meier 方法,p<0.01)和严重程度(r=0.75)相关。接种前 CRP、TSH 和甲状腺过氧化物酶抗体(anti-TPO)与情绪变化的发生率相关。
COVID-19 疫苗接种似乎会导致 HT 患者 TSH 水平升高和发生率增加,继而引起情绪变化。接种前血清 TSH、CRP 和 anti-TPO 值较高与接种后早期更高的发生率相关。